Background. Acute kidney injury (AKI), accompanied by the development of systemic inflammatory response syndrome and multiorgan dysfunction syndrome, is associated with a high risk of death. Bioartificial renal tubule device (BTD) is a cell therapy that improves the conditions common to artificial kidney recipients treated for kidney diseases. In this paper, we describe the establishment of BTD with lifespan-extended human renal proximal tubular epithelial cells. Methods. AKI goats were established by performing bilateral nephrectomy followed by lipopolysaccharide administration. The AKI goats were treated with BTD or sham-BTD, and the two groups of animals were compared by measuring the respective life spans and the levels of blood urea nitrogen, creatinine, alanine aminotransferase, aspartate aminotransferase, lactate dehydrogenase and serum electrolytes. The expression levels of inflammatory cytokines were detected by reverse transcription-polymerase chain reaction, and plasma interleukin (IL)-6 levels were measured by enzyme-linked immunosorbent assay. Results. The life span of AKI goats was extended: the lifetime with the BTD treatment compared with sham-BTD. BTD and sham-BTD showed a similar degree of small solute clearance. The expression levels of inflammatory cytokines and plasma IL-6 levels were decreased by the BTD treatment. Conclusions. BTD treatment results in less damage from endotoxin shock and increased life span in AKI goats. These results suggest that BTD may be a useful component of bioartificial kidneys and should be considered in the next generation of renal replacement therapies.
Introduction
The development of severe acute kidney injury (AKI) is accompanied by systemic inflammatory response syndrome and multiorgan dysfunction syndrome, leading to a high risk of death. Renal replacement therapies using artificial kidneys, such as hemofiltration and hemodialysis, are the most widely applied therapy and play an important role in the treatment for AKI. Despite many improvements in blood purification methods with respect to the composition and purity of dialysis fluid, permeability and biocompatibility of dialysis membranes and alternative systems in combination with diffusion and convection, the common artificial kidney does not substitute for the reabsorptive, metabolic, immunomodulation and endocrine functions of the renal tubule [1, 2] .
Cell therapy is a new therapeutic approach for the repair of diseased organs and for the replacement of function in failed organs [3] . Bioartificial renal tubule device (BTD), also called renal tubule assist device, is a cell therapy for patients with kidney failure. This cell therapy is accomplished by placing renal tubule cells, primary cells or cell lines established from various species, on the inner surface of hollow fibers in BTD. These cells are expected to compensate for renal functions not addressed by common renal replacement methods, by proving renal cell components involved in reabsorption, metabolic activities, immunomodulation and endocrine functions [4, 5] . After the first introduction of BTD by Aebischer et al. [6] , our group and others applied the BTD approach and have reported several advances in the development of bioartificial kidneys [1, 2, [7] [8] [9] [10] [11] . Recently, a human clinical trial has been reported in the USA [12, 13] ; however, this technology is not yet approved for commercial application.
A major obstacle in BTD preparation is obtaining a sufficiently large number of renal proximal tubular epithelial cells (RPTEC) for covering the inner surface of the hollow fibers. To address this problem, renal tubular cell lines such as LLC-PK 1 from porcine [14] [15] [16] [17] , JTC-12 from monkey [18] and MDCK from canine [6, 19, 20] have been used as functional cells. However, the cell lines often formed multilayered structures via uncontrolled growth and followed by loss of cell viability, polarization and function, leading to disturbed flow in the lumen [16] . In our previous report, we developed BTD prepared with lifespan-extended human RPTEC [21] . The lifespanextended human RPTEC enhances the ability of normal human RPTEC replication by silencing cell cycle-related genes using RNAi technology. These cells proliferate logarithmically unless discontinued by small interfering RNA (siRNA) treatment and exhibit properties identical to the normal RPTEC, without uncontrollable proliferation or carcinogenesis. Therefore, we introduced these cells for preparing BTD instead of the normal primary RPTEC.
Here, we describe and evaluate the function of BTD prepared with lifespan-extended human RPTEC using AKI goats treated with BTD or sham-BTD (BTD without cells, as a control). Our results show that while there was no significant difference in the serum metabolite levels between the groups of AKI goats, the survival time was increased, and the production of inflammatory cytokines was reduced in AKI goats treated with BTD. These results suggest that BTD may be an important development for clinical use in future.
Materials and methods
The protocol for this study was approved by the Institutional Review Board of Tokai University School of Medicine. Use of human materials was permitted by patients' informed consent.
RPTEC and BTD
Procedures describing the preparation of human RPTEC and the construction of BTD were described in our previous report [21] . In brief, human kidney cells were prepared from patients undergoing renal carcinoma surgeries, with their consent, and RPTEC were isolated using immunomagnetic separation [22] . The isolated cells were cultured in renal epithelial growth medium (Lonza, Basel, Switzerland), and the media were changed every other day. When the cells grew to a subconfluent stage, the cells were transfected with p16
INK4a siRNA to extend their replicative life span.
Ethylene vinyl alcohol hollow fiber modules (0.8 m 2 , KF-08C; Asahi Kasei Kuraray Medical, Tokyo, Japan) were used for constructing BTD. The inner surface of the hollow fibers was coated with attachin (10 μg/ mL, Bio999; Taipei, Taiwan). RPTEC (total, 3-7 × 10 8 cells) were inoculated in the lumen rotating the module four times by 90°. The culture medium was circulated in the outer compartment of the module for 1 h, followed by circulation in the inner compartment at the same rate. The medium was changed every day during closed-circuit perfusion for at least a week.
AKI animal model
For generating an AKI animal model, we established uremic goats by subjecting them to bilateral nephrectomy. Care of all goats used in these experiments was in accordance with the Guidelines for Proper Conduct of Animal Experiments (Science Council Japan, 2006). All castrated male goats (Japanese Saanen; 32-50 kg, 39.3 ± 5.0 kg), purchased from Inoue Shoten (Gunma, Japan), tested negative for sugar, protein and occult blood in the urine. Before beginning the experiments, the goats were allowed to acclimate for at least a week to the experimental environment in the animal experiment room maintained at controlled temperature and humidity. Goats were fed a low-protein diet, followed by 24-h fasting before the operation. Each goat was pre-medicated with xylazine (0.3 mg/kg) intramuscularly for restraint, and endotracheal anesthesia was induced using isoflurane (0.5-2.5%) and nitrous oxide (30-70%) with a mechanical ventilation (Harvard Apparatus, Holliston, MA). The heart rate, blood pressure and oxygen saturation of the animals were monitored during the surgical procedure. Goats were catheterized via the carotid artery and jugular vein as the access to the extracorporeal blood circuit. Following installation of the catheter, the goats were nephrectomized bilaterally. After the surgery, the catheters were filled with heparin to avoid blood coagulation and formation of thrombus in the tubes. Artificial ventilation was continued until the emergence of goats. Following the procedure, goats were given water and fed a low-protein diet until the end of the experiment.
Extracorporeal circulation
At 48 h after the nephrectomy, catheters were connected to the BTD circuit. A schematic of the circuit is shown in Figure 1 . The hemofilter was supplied from Nipro (Osaka, Japan). Sublood-BS (Fuso Pharmaceutical, Osaka, Japan) was used as the replacement solution. Heparin (Heparin sodium injection-N; Ajinomoto, Tokyo, Japan) in saline was continuously infused at 1000-2000 U/h in this line as an anticoagulant. During circulation, BTD was warmed at 37°C by the water jacket.
After 2 h of circulation, lipopolysaccharide (LPS, 5 × 10 5 IU/kg; Sigma, St. Louis, MO) was injected into the extracorporeal circulation unit taking for 2 h. A small amount of blood was collected from the circulation intermittently, and concentrations of blood contents (Table 2) were determined using clinical laboratory assays.
The extracorporeal circulations were terminated at 24 h after the initiation of LPS administration (26 h from the circulation). Blood sampling and animal observation were continued until the end of the experiments. Blood pressure was measured intermittently with monitoring machine (Nihon Kouden Kougyou, Tokyo, Japan) by connecting pressure sensor to the carotid artery through the inserted catheter.
Reverse transcription-polymerase chain reaction
Goat peripheral blood mononuclear cells (PBMCs) were isolated from heparinized whole blood using Histpaque 1077 (Sigma). The total RNA was prepared from PBMC using an RNAqueous-4PCR kit (Ambion, Austin, TX), and the first-strand DNA was synthesized by SuperScript III Fig. 1 . Schematic of the extracorporeal circuit for the bioartificial kidney. A conventional hemofilter is set in series with BTD. Arterial blood was driven through the catheter with an infusion pump into the hemofilter (0.3 m 2 ). After the hemofilter separated the ultrafiltrate and the filtered blood, the ultrafiltrate passed through the luminal space (14 mL/min) and the filtered blood flowed into the extracapillary space (70 mL/min) of the BTD. The ultrafiltrate flowing through BTD was replaced as the waste with the replacement solution (Na : 35 mEq/L and glucose 100.0 mg/dL) at the rate of 10 mL/mL for the restoration of fluid in the circulation and then blood in the extracorporeal circuit returned to the goat through the catheter in the vein. P: pump.
(Invitrogen, Carlsbad, CA). Quantitative reverse transcription-polymerase chain reaction (RT-PCR) reactions were conducted using Fast SYBR Green Master Mix (Applied Biosystems, Carlsbad, CA) and the primer pairs listed in Table 1 . The PCR was performed on ABI PRISM7500 (Applied Biosystems), and relative amounts of target messenger RNAs (mRNAs) to mRNA of β-actin were calculated.
Enzyme-linked immunosorbent assay
Interleukin (IL)-6 in the goat serum was measured by enzyme-linked immunosorbent assay (ELISA) using anti-sheep IL-6 antibody pairs, monoclonal (clone 4B6) and polyclonal antibodies (Millipore, Billerica, MA). Firstly, we confirmed that the anti-sheep IL-6 antibody pairs reacted with recombinant goat IL-6, prepared in Escherichia coli (data not shown). ELISA was conducted on micropletes (Maxsorb; Nunc) as previously reported by McWaters et al. [23] .
Statistics
Data are presented as mean ± SD. Student's t-test was used to compare data. P-values for statistical significance are as indicated.
Results

Bilateral nephrectomized goats as AKI animal model
We established renal failure goats as an AKI animal model by subjecting goats to bilateral nephrectomy followed by LPS administration. Before the nephrectomy, the uremic markers, namely, blood urea nitrogen (BUN) and creatinine (Cr) showed normal levels (BUN: 7.7 ± 5.1 mg/dL, Cr: 0.46 ± 0.10 mg/dL). After the operation, uremia progressed gradually, and BUN and Cr levels increased (BUN: 79.2 ± 21.0 mg/dL, Cr: 7.76 ± 0.86 mg/ dL) by starting the extracorporeal circulation with hemofilter and BTD at 48 h later. The organ damage especially liver damage markers aspartate aminotransferase (AST), alanine aminotransferase (ALT) and lactate dehydrogenase (LDH) were found to be increased after the nephrectomy [AST: 58.6 ± 12.2 to 82.0 ± 25.0 U/L (P < 0.01), ALT: 17.1 ± 4.2 to 20.9 ± 5.3 U/L (P < 0.01) and LDH: 270.4 ± 58.9 to 422.4 ± 135.6 U/L (P < 0.01)]. A nephrectomized goat survived ∼4 days without the extracorporeal circulation and LPS administration. The administration of LPS induced endotoxin shock, with sepsis and multiorgan dysfunctions. The severe AKI goats without the extracorporeal circulation survived no more than 8 h after LPS administration ( Figure 2b ) and displayed symptoms of severe AKI such as hypercytokinemia, diarrhea, hemolysis, dehydration and organ damage. Therefore, we performed the subsequent experiments using the AKI goat as the animal model.
Extension of survival time of AKI goats by BTD
To evaluate the function of BTD, we established three groups of goats, each group containing eight animals. The groups were as follows: AKI goats without circulation (non-treatment). AKI goats treated with BTD with the lifespan-extended RPTEC and AKI goats treated without the cells (sham-BTD) in the extracorporeal circulation. The goats were randomly designated to each group by the supplier, and the characteristics such as body weight were not significantly different among the experimental groups. The results show that the survival times of AKI goats treated with LPS were extended by the extracorporeal circulation, especially by the BTD (Figure 2 ). The average survival time after the start of LPS administration was 5.5 ± 1.6 h without circulation. Circulation with sham-BTD tended to extend the survival time to 9.3 ± 5.4 h. BTD in the extracorporeal circulation for the AKI goat significantly extended the survival time to 24.0 ± 10.7 h as compared to the non-treatment or sham-BTD (P < 0.01) (Figure 2a) . No AKI goat survived 24 h following LPS administration without the cell-BTD, dying by 8 h for non-treatment and 19 h for sham-BTD. In contrast, half of the AKI goats with BTD still survived when the extracorporeal circulation terminated after 24 h from the initiation of LPS administration (Figure 2b ). The BTD treatment significantly extended the lifetime of the AKI goat (P = 0.002). The cells in BTD were still viable and were attached to the surface of the hollow fibers (data not shown). After termination of extracorporeal circulation, the AKI goats died, with the longest animal survival time being 37 h after LPS administration. Figure 3 shows representative changes of blood pressures of three groups. Those showed quick elevation after initiation of LPS injection at 2 h of the circulation, but soon decreased. In cases of non-treated and sham-BTD groups, the severe hypotension continued until death, while it was somewhat slower in the sham-BTD group. These hypotensions were considered to be brought from circulation failure as endotoxin shock. In contrast, normotension was observed during the circulation in the BTD group. Severe hypotension occurred just after the detachment of BTD in all goats alive at that moment, at 26 h from the initiation of the circulation.
Changes in plasma markers of AKI goats by BTD
The concentrations of various plasma constituents from AKI goats treated with BTD or sham-BTD are summarized in Table 2 . These data represent the plasma values sampled during the time course of the extracorporeal 7.7 ± 0.5 7.6 ± 0.5 7.5 ± 0.5 7.5 ± 0.6 6.7 BTD 8.1 ± 0.7 7.7 ± 0.8** 7.2 ± 0.5* 7.5 ± 0.6** 7.0 ± 0.5** 6.7 ± 0.4* 6.7 ± 0.5** 6.5 ± 0.2* 6.6 ± 0.5* 7.0 ± 0.5** 6.9 ± 0.6** Inorganic phosphate (5.7 ± 1.6 mg/dL) Non N/A 6.2 ± 3.1 6.7 ± 2.7 8.1 ± 4.2 7.9 ± 3.8 Sham 4.8 ± 1.1 5.0 ± 1.3 5.5 ± 1.6 5.8 ± 1.4 7.0 ± 1.2** 7.9 ± 1.5** 8.2 ± 1.5** 8.0 ± 1.3 7.4 BTD 5.5 ± 1.9 5.1 ± 2.0 4.6 ± 1.6 5.4 ± 1.7 5.5 ± 1.5 6.3 ± 1.7 6.5 ± 1.6 6.3 ± 1.9 5.7 ± 1.3 5.6 ± 1.3 6.5 ± 3.5 circulation. After LPS administration to the AKI goats, the uremic markers BUN and serum Cr gradually increased in the absence of circulation, while BUN and Cr levels decreased slightly but significantly with circulation. These results show that the extracorporeal circulation preserved or slightly reduced exacerbation of uremia. The plasma levels of the organ damage markers AST, ALT and LDH were increased with time after LPS administration, and circulation did not influence these marker levels.
These results indicate that organ damage seemed to have been proceeding during the extracorporeal circulation. The blood levels of the electrolytes, sodium (Na) and chloride (Cl) remained unchanged during circulation, indicating that the body fluid volume was maintained at the same levels. Calcium (Ca) was slightly decreased during the circulations, presumably owing to the lack of activation of vitamin D on renal cells due to the nephrectomy. On the other hand, potassium (K) was decreased at 2 h after LPS injection, even without circulation, but thereafter increased gradually. This incremental increase was presumably caused by the destruction of cells, including hemolysis by LPS treatment. Uric acid was decreased until 4 h after the start of the circulation and thereafter tended to increase, especially just before the end of the experiment. Inorganic phosphate increased in the middle of circulation but slightly decreased at the end of the experiments. The normal serum glucose level of goats was lower (62.4 ± 10.2 mg/dL) than that of humans. Hyperglycemia was markedly induced by LPS infusion and then suddenly hypoglycemia was observed in all groups. The number of white blood cells was dramatically decreased by LPS treatment and gradually recovered by the end of the extracorporeal circulation in cases where the goat survived. All these described plasma marker results, however, did not significantly differ between the circulation with BTD and sham-BTD.
Reduction of cytokine production by BTD
Using RT-PCR detection methods, the expression levels of inflammatory cytokines in PBMC during the extracorporeal circulation were analyzed. These cytokines included IL-6, IL-1β, tumor necrosis factor (TNF)-α and interferon (IFN)-γ and an anti-inflammatory cytokine, IL-10. In this study, LPS was continuously injected for 2 h (from 2 h to 4 h of circulation time in Figure 4 ). The cytokines were produced at low levels before LPS treatment but were then dramatically increased and produced maximally at 2 h after the start of LPS administration. Cytokine expression was maintained at nearly the same level, up to 8 h of LPS administration during sham-BTD treatment. On the other hand, cytokine expression in PBMC was reduced at 4 h after the start of LPS administration in BTD-treated goats. Therefore, it seemed that the cytokines were expressed during LPS injection but were suppressed immediately by the BTD treatment. The serum IL-6 level was also reduced significantly by BTD (Figure 5a ). The IL-6 levels in sham-BTD-treated goats were 656.5 ± 105.3 μg/mL, while those in BTD-treated goats were 351.3 ± 70.5 μg/mL at 6 h after the LPS treatment (Figure 5b ). The amount of serum IL-6 in BTD-treated goats was almost half the level as that measured in sham-BTD goats. These results suggest that the BTD treatment not only reduces the cytokine expression levels but also the secretion level. The reduction of these cytokines may have alleviated severe inflammation and improved survival from AKI.
Discussion
Despite progress in clinical renal replacement therapies, uremic conditions and dysregulation of inflammatory response continue to signal poor prognosis in AKI patients and are associated with severe dialysis-related complications in chronic dialysis patients. The addition of BTD may improve current renal replacement therapy [2, 21] . In BTD preparation, several important factors need to be considered, such as the housing of devices, materials of hollow fibers and matrices for cell attachment. One of the most critical factors in BTD is preparing a sufficiently large number of human RPTEC for covering the inner surface of hollow fibers since primary RPTEC proliferation is usually arrested at ∼10 cell divisions [21] . This limitation on cell number requires a stable supply of the organs for clinical use in the future. Therefore, we employed RNAi technology to develop RPTEC that retained renal cell functions and had an extended life span. The siRNAs against the cell cyclerelated genes blocked the expression of the cell cycle inhibitors, allowing more RPTEC growth than the previous limit of cell division. This method makes more than a billon cells from one RPTEC. Unlike cell lines, we can control cell proliferation by interrupting siRNA treatment. Moreover, the cells retain properties of the primary PRTEC, such as gene expressions and functions. Therefore, we prepared BTD with lifespan-extended RPTEC and used them to treat AKI goats as an animal model.
Using goats as the animal model has the following advantages: they are representative of the body size of a human and are relatively docile for experimental handling. Other researchers have used pigs [24] [25] [26] and dogs [4, 5, 27, 28] as the animal model. Generally, the body weight of pigs or dogs is <30 kg, while Japanese Saanen goats weighed 32-50 kg (39.3 ± 5.0 kg). Moreover, goats are known to have more circulating blood than pigs and dogs and may suffer less damage from the decrement of blood during the extracorporeal circulation. Hence, using goats for evaluating extracorporeal circulation enabled similar representation to the conditions found in humans. On the other hand, antibodies against goat proteins are usually not commercialized and are less readily available. Fortunately, we found sheep IL-6 antibodies that react with goat IL-6, but not for other cytokines. Therefore, we deduced the production levels of other cytokines as the expression levels in PBMC using RT-PCR, except for IL-6.
Treatment of AKI goats with BTD did not result in significant differences in serum biochemical components compared with the treatment of AKI goats with sham-BTD. Therefore, these two devices seemed to achieve a similar degree of small solute clearance. From changes of blood pressures and these data, direct cause of death of the AKI goats is considered to be circulation failure. The circulation failure was avoided during the BTD treatment in the AKI goats with endotoxin shock. It is speculated that the circulation failure was induced by overproduction of nitric oxide derived from hypercytokinemia in the AKI goats injected excess amounts of LPS. BTD-treated AKI goats survived longer and showed reduced cytokine production compared with sham-BTD-treated AKI goats. In previous studies using BTD in pig or dog models, the serum levels of inflammatory or anti-inflammatory cytokines were measured, but the results were variable on the reports. Wang et al. The serum IL-6 levels of AKI goats treated with BTD or sham-BTD (mean ± SD, n = 8). For measurement of goat IL-6, microtiter plates were coated with 0.5 μg of mouse antisheep IL-6 monoclonal antibody in 100 μL of 50 mM carbonate buffer ( pH 9.6) for each well at 4°C overnight. After blocking each well with 200 μL of 0.1% skimmed milk in phosphate-buffered saline, the samples were put into the wells and incubated at room temperature for 1 h. The wells were washed with phosphate-buffered saline containing 0.05% Tween 20 (PBST) and added with 100 μL of rabbit anti-sheep IL-6 polyclonal antibody (1:500) diluted in PBST was added, followed by 1-h incubation at room temperature. After washing with PBST, 0.5 μg of horseradish peroxidase-labeled anti-rabbit IgG in 100 μL of PBST for each well was added, followed by a 30-min incubation at room temperature. After washing, 100 μL of tetramethyl benzidine chromogen was added, followed by incubation for 5-10 min at room temperature. To stop the horseradish peroxidase reactions, 100 μL of 2 N sulfuric acid was added and absorbance was measured at 450 nm on a microplate reader. Several doses of quantified recombinant goat IL-6 were used for generating the standard curve for quantification.
reported a significant increase in the IL-10 and decrease in the TNF-α level, but no difference in the IL-6 level in the pig models of ischemic renal injury [25, 26] . On the other hand, Humes et al. reported decreases in the IL-6 and IFN-γ and an increase in the IL-10 level, but no change in the TNF-α, IL-1, IL-2, IL-4 and IL-8 levels measured in endotoxin-induced septic shock dogs or pigs that had undergone bilateral nephrectomy [24, 27, 28] . Therefore, in both groups, the IL-10 level increased, and the IL-6/IL-10 ratio decreased. In our results, all cytokines analyzed, including IL-10, were decreased by BTD treatment, and the levels were maintained by sham-BTD treatment. The possible reasons for the difference in IL-10 levels between our results and others may be the difference in the animal type or detection methods. We detected cytokines in terms of mRNA expression levels determined using RT-PCR because the antibodies for ELISA assay were not available. In the human clinical trial, the IL-6 and IL-10 levels and the ratio of IL-6/IL-10 were decreased by BTD treatments [12] . Therefore, the ratio of IL-6/IL-10 may be affected in our study. IL-6, IFN-γ, TNF-α and IL-1β are important inflammatory cytokines that are directly correlated to the clinical outcome of sepsis, multiorgan dysfunction syndrome and systemic inflammatory response syndrome [29] [30] [31] [32] . IL-10 is an important anti-inflammatory cytokine that regulates the immunoreactions during infection and can suppress the secretion of inflammatory cytokines such as TNF-α and IL-1β. IL-10 can ameliorate septic shock in mouse models [33, 34] and improve survival, even if it is administered after clinical signs of illness are presented [35] . The renal tubule cells have a role in immunoregulatory function [28] . Our results suggest that the extension of life span of AKI goats by the BTD treatment is, at least partially, related to the immunoregulatory function. Although the mechanism for the suppression of inflammatory cytokine production is still not clear, if the mechanism is elucidated, a new treatment will be possible for AKI and other inflammatory diseases. Further experiments are required to examine the mechanism of observed suppression of inflammatory cytokine production.
Another cell source for BTD can be human stem cells. Recently, various human stem cells such as bone marrow stem cells, embryonic stem (ES) cells and induced pluripotent stem (iPS) cells have been introduced and used to induce the differentiation of several lineages, such as pancreatic β-cells [36] , hepatocytes [37] and cardiomyocytes [38] . ES cells have been used in clinical trials for the treatments of spinal cord injury and macular degeneration. Recently, Morizane et al. [39] have reported the differentiation of murine ES and iPS cells into the renal lineage. Even with these developments, the induction of differentiation into RPTEC from human stem cells remains to be elucidated. If the differentiation into human RPTEC in vitro is possible, we can more easily and stably collect large numbers of RPTEC for preparing BTD for clinical treatment by the combination of cell differentiation and the life span extension. Thus, using iPS cells prepared from their own cells as the cell source, iPS-BTD can be also applied for patients of chronic kidney disease.
Conclusions
In conclusion, AKI goats treated with BTD showed increased life span and reduced damage from endotoxin shock. These results suggest that BTD may be a useful device for bioartificial kidney therapy and warrants further exploration in future renal replacement therapies.
